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ABSTRACT 
Objective: To perform an in vitro equivalence study of two doses of carbamazepine reference tablets sold in the local market under hydrodynamic 
conditions of USP Apparatus 4, a dissolution apparatus that better simulates the human gastrointestinal tract. Results were compared with 
dissolution official conditions using USP Apparatus 2. 
Methods: Dissolution profiles of both formulations were carried out with an automated USP Apparatus 2 at 75 rpm and 900 ml of dissolution 
medium. USP Apparatus 4 with laminar flow at 16 ml/min and 22.6 mm cells were used. 1% lauryl sulfate aqueous solution at 37.0±0.5 °C was used 
as dissolution medium. Spectrophotometric determination of drug at 285 nm was carried out during 60 min. Dissolution profiles were compared 
with model-independent and-dependent approaches. 
Results: When comparing dissolution profiles of low vs. high dose similar profiles were found (f2
Conclusion: Equivalent dissolution performance of two doses of carbamazepine reference tablets were found in each USP dissolution apparatus. 
>50) in each dissolution apparatus, however, when 
the same dose was compared, USP 2 vs. USP 4, opposite results were obtained. Comparison of mean dissolution time and dissolution efficiency data 
corroborates these results. Weibull function was the best mathematical model that described the in vitro dissolution performance of carbamazepine. 
No significant differences were found in Td values (low vs. high dose) but opposite results were also found with USP 2 vs. USP 4. 
The main problem identified in this comparative study is the low dissolution rate and extent found with USP Apparatus 4. More research on this 
field is necessary for all available doses of reference drug products since the quality of generic formulations depends on the quality of references
Keywords: Carbamazepine, Flow-through cell method, Reference drug products, USP Apparatus 4 
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Dissolution test is an important tool to ensure lot-to-lot good quality 
and after some manufacture, changes as well as for determination of 
interchangeability among generic formulations. These formulations 
have the same pharmacological effect with the benefit of lower costs 
for patients and hospitals. Generic drug products should 
demonstrate the same in vitro dissolution performance of reference 
drug products so, quality of generic drug products depends of the 
quality of references. Due to the high cost of bioequivalence studies 
and information of Biopharmaceutics Classification System (BCS) 
about solubility and permeability of some drugs, Guidelines for 
Industry-based on BCS have established criteria by which 
bioequivalence studies can be replaced by in vitro dissolution 
studies [1]. This waiver is based mainly on the fulfillment of f2 
similarity factor between dissolution profiles of test and reference 
(f2>50) using dissolution media with pH of physiological relevance 
as well as compliance with related criteria to the excipients used in 
the formulation manufacture [2]. Some biowaiver monographs have 
been published for class I and III drugs (high solubility drugs) [3] 
 
but for its physicochemical and clinical characteristics, no biowaiver 




1: Molecular structure of carbamazepine 
Carbamazepine is a poorly soluble drug with a narrow therapeutic 
window used to treat epilepsy and other neurological disorders as 
trigeminal neuralgia [4]. Molecular structure of carbamazepine is 
shown in fig. 1. The drug is available as generic drug products and 
Mexican health authorities request bioequivalence studies to 
approve the marketing of these formulations. Considering BCS 
criteria carbamazepine has been classified as a class II drug (low 
solubility/high permeability) and for its low solubility, dissolution 
problems of two different doses in the same volume of dissolution 
medium could be observed. Class II drugs are expected to have a 
dissolution-limited absorption and a significant in vitro/in vivo 
correlation (IVIVC) should be expected using a well-designed in vitro 
dissolution test. 
Official d
For multiple strengths of immediate-release products with linear 
kinetics, the bioequivalence study may be performed at the highest 
strength and waivers of in vivo studies may be granted on lower 
strengths, based on an adequate dissolution test, provided the lower 
strengths are proportionately similar in composition [5]. It is 
possible that this assertion does not apply to carbamazepine 
however, it is important to investigate the in vitro dissolution 
performance of two doses of carbamazepine reference tablets under 
hydrodynamic environments generated by commonly used 
dissolution apparatuses with the aim of gather information to 
suggest a biowaiver mechanism for carbamazepine drug products, 
starting at least, with the available doses of reference and 
pharmacopeial conditions. 
issolution test for carbamazepine tablets is described in 
United States Pharmacopoeia (USP) [6]. The method indicates the 
use of USP Apparatus 2 (paddle) at 75 rpm and 900 ml of 1% sodium 
lauryl sulfate aqueous solution at 37.0±0.5 °C as dissolution medium. 
Under these conditions and for carbamazepine immediate-release 
tablets labeled as 200-mg there are two tests with the following 
times and tolerances: TEST 2 between 45 and 75% of the labeled 
amount of carbamazepine is dissolved in 15 min; not less than 75% 
(Q) of the labeled amount of carbamazepine is dissolved in 60 min 
and TEST 3 between 60 and 85% of the labeled amount of 
carbamazepine is dissolved in 15 min; not less than 75% (Q) of the 
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labeled amount of carbamazepine is dissolved in 60 min. However, 
some authors reported lack of correlation between in vitro data 
using these conditions and in vivo results [7, 8]. 
A dissolution equipment different to USP Apparatus 1 (basket) and 2 
(paddle) is USP Apparatus 4 (flow-through cell method) [9, 10]. Its 
advantages, over USP basket and paddle apparatuses, have been widely 
demonstrated especially in the study of dissolution performance of 
poorly soluble drugs [11, 12]. The flow-through cell method has a 
continuous extraction of the drug, simulating the absorption into the 
systemic circulation, generating an intermittent flow of dissolution 
medium into the cells where the tablets are placed [13]. USP Apparatus 4 
can be used as an open system that operates under sink conditions which 
facilitates the dissolution of poorly soluble drugs as well as changing the 
dissolution medium throughout the test [14]. Flow-through cell method 
better simulates the hydrodynamic environment found in the 
gastrointestinal tract and some authors have demonstrated that in vitro 
data obtained with flow-through cell method better reflect in vivo 
performance of drugs with solubility problems [15, 16]. Despite the 
advantages of USP Apparatus 4, information about dissolution 
performance of commercially available doses of carbamazepine 
reference tablets under hydrodynamic environment generated by the 
flow-through cell method is scarce. 
The main objective of this in vitro equivalence study was to evaluate 
the release performance of two doses of carbamazepine reference 
tablets under the hydrodynamic environment generated by USP 
Apparatus 4. Data obtained were compared with the pharmacopeial 
test that uses USP Apparatus 2. The results could be of interest for 
pharmaceutical laboratories or health authorities that classify some 
drug products as a reference to be used in dissolution and 
bioequivalence studies. 
MATERIALS AND METHODS 
Materials 
In this pharmaceutical equivalence study carbamazepine tablets 
(Tegretol® 200-mg, lot TL005, round tablets of 9×3.7 mm and 
Tegretol® 400-mg, lot TL534, cuboid tablets of 17×5.5×5.1 mm; 
Novartis Farmacéutica SA de CV) from the Mexican market were used. 
National health authorities (COFEPRIS) has established this brand as a 
reference for bioequivalence studies [17]. Sodium lauryl sulfate was 
purchased from Distribuidora Química Lufra-México. Carbamazepine 
standard was purchased from Sigma-Aldrich Co. (St. Louis MO, USA). 
Content uniformity and assay 
Content uniformity and assay tests were performed on both drug 
products, according to the procedures described in USP [6]. 
Dissolution profiles 
USP Apparatus 2 
Dissolution profiles of carbamazepine were determined according to 
USP test [6] in an automated USP paddle apparatus (Sotax AT-7 
Smart, Switzerland) with a piston pump (Sotax CY7-50, 
Switzerland). An UV/Vis spectrophotometer with 1 mm flow cells 
(Perkin Elmer Lambda 35, USA) was used. All equipment and data 
generated were controlled by specific software designed by Sotax. 
Both doses of carbamazepine reference tablets were sprinkled on 
900 ml of 1% sodium lauryl sulfate aqueous solution at 37.0±0.5 °C 
as dissolution medium. The rotational speed of 75 rpm was tested. 
Sequential sampling using 0.45 µm nitrocellulose filters (Millipore®) 
occurred over 60 min at regular 5 min intervals with 12 replicates. 
The amount of carbamazepine dissolved was determined with a 
standard calibration curve at 285 nm. 
Dissolution profiles of both doses of carbamazepine tablets were 
obtained in an automated flow-through cell apparatus 4 (Sotax CE6, 
Sotax AG, Switzerland) with 22.6 mm cells (i.d.) and a piston pump 
(Sotax CY7-50, Sotax AG, Switzerland). Laminar flow (with a bed of 6 
g of glass beads) was used. The degassed dissolution medium, 1% 
sodium lauryl sulfate aqueous solution at 37.0±0.5 °C was pumped 
at a flow rate of 16 ml/min. An open system was used, without 
recycling the dissolution medium. Sequential sampling using 
nitrocellulose filters was set at regular 5 min intervals over 60 min, 
with 12 replicates. The amount of carbamazepine dissolved was 
determined in an UV/Vis spectrophotometer with 1 mm cells 
(Perkin Elmer Lambda 10, USA) at 285 nm. For every trial, a 
standard calibration curve was prepared. 
USP Apparatus 4 
Data analysis 
Dissolution profiles of carbamazepine (low vs. high dose) were 
compared using model-independent and-dependent methods. For 
model-independent methods f2 similarity factor, mean dissolution 
time (MDT) and dissolution efficiency (DE) were calculated. Mean 
values were compared by a Student’s t-test and significant 
differences were considered if *P<0.05. For model-dependent 
comparisons, dissolution data were adjusted to First-order, Higuchi, 
Korsmeyer-Peppas, Hixson-Crowell, Makoid-Banakar, Weibull and 
Logistic model. The model with the highest determination coefficient 
(R2 adjusted
 
) and lowest Akaike information criterion (AIC) was chosen 
as the best-fit model [18]. Data analysis was carried out using the 
Excel add-in DDSolver program [19]. Mathematical equations used 
to fit carbamazepine dissolution data are shown in table 1. 
Table 1: Mathematical equations used to fit dissolution data 
Model Equation 
First-order 𝐹𝐹 = 100 ∙ (1 − 𝑒𝑒−𝑘𝑘1∙𝑡𝑡) 
Higuchi 𝐹𝐹 = 𝑘𝑘𝐻𝐻 ∙ 𝑡𝑡0.5 
Korsmeyer-Peppas 𝐹𝐹 = 𝑘𝑘𝐾𝐾𝐾𝐾 ∙ 𝑡𝑡𝑛𝑛  
Hixson-Crowell 𝐹𝐹 = 100[1 − (1 − 𝑘𝑘𝐻𝐻𝐻𝐻 ∙ 𝑡𝑡)3] 
Makoid-Banakar 𝐹𝐹 = 𝑘𝑘𝑀𝑀𝑀𝑀 ∙ 𝑡𝑡𝑛𝑛 ∙ 𝑒𝑒−𝑘𝑘 ∙𝑡𝑡  
Weibull 





𝐹𝐹 = 100 ∙
𝑒𝑒𝛼𝛼+𝛽𝛽 ∙𝑙𝑙𝑙𝑙𝑙𝑙 (𝑡𝑡)
1 + 𝑒𝑒𝛼𝛼+𝛽𝛽 ∙𝑙𝑙𝑙𝑙𝑙𝑙 (𝑡𝑡)
 
 
RESULTS AND DISCUSSION 
Content uniformity and assay 
All carbamazepine drug products were within USP limits. The 
percentages of carbamazepine on content uniformity test ranged from 
85-115% and assay test between 90-110%. Results are shown in table 2. 
In vitro dissolution performance 
Dissolution profiles of two doses of carbamazepine reference tablets, 
in both USP Apparatuses, 
 
are shown in fig. 2. To compare the 
dissolution process between doses, Y-axis is expressed as the 
percentage of drug dissolved. 
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Table 2: Content uniformity and assay results, mean, n = 10*, n = 3† 
Dose Content uniformity (min-max)* Assay (%)† 
Low 95.26–96.49 96.10 





2: Dissolution profiles of carbamazepine from two doses of reference tablets. Slashed line shows tolerances of TEST 2 and continuous 
line shows tolerances of TEST 3. mean±SD, n = 12 
Carbamazepine 200-mg reference tablets et al. l dissolution 
tolerances only when tests were carried out with USP Apparatus 2. 
Tolerance of USP TEST 2 at 15 min is 45-75% of drug dissolved and 
at 60 min not less than 75% of drug dissolved should be found while 
tolerance of TEST 3 at 15 min is 60-85% of drug dissolved and at 60 
min not less than 75% of drug dissolved should be found. These 
criteria were also fulfilled by carbamazepine 400-mg tablets. With 
flow-through cell method, any dissolution criteria were fulfilled. 
In each USP dissolution apparatus, similar dissolution profiles of low 
vs. high dose were found, f2 = 94.46 when USP Apparatus 2 was used 
and f2 = 66.51 when USP Apparatus 4 was used. On the other hand, 
and despite the obvious differences in dissolution profiles of both 
carbamazepine doses, between USP Apparatuses 2 and 4, f2 
similarity factors were also calculated and results were 12.99 when 
the dose of 200-mg was compared and 11.36 when dose of 400-mg 
was compared. A limited dissolution of 200-mg reference tablets 
was also reported by Medina et al., [20] when simulated gastric fluid 
without pepsin and flow-through cell method were used. Values of 
17.99% as drug dissolved at 60 min and 9.81% as DE were found. 
With USP Apparatus 4 both formulations showed a slower 
dissolution rate than that found with USP paddle apparatus. Some 
authors have published that this performance can be explained by 
the hydrodynamic conditions found in USP Apparatus 4, where there 
are no agitation mechanisms and the dosage form and drug particles 
are continuously exposed to a uniform laminar flow, similar to the 
natural environment of the gastrointestinal tract, causing a different 
dissolution pattern [21]. In the flow-through cell method, cell size, 
glass beads and flow rate are critical factors to form this dissolution 
pattern. Considering USP Apparatus 4 as a dissolution apparatus 
that better simulates in vivo conditions and for the low dissolution 
rate and extent observed with this apparatus clinical problems of 
carbamazepine could be explained. 30% of patients with focal 
epilepsy do not respond to maximum dosages of carbamazepine 
resulting in the need to administer polytherapy with additional 
antiepileptic drugs to control seizures [22]. 
Model-independent comparisons 
 
Percentage of carbamazepine dissolved at 15 and 60 min and 
model-independent parameters MDT and DE mean 
values±standard error medium (SEM) are shown in table 3. Data of 
low vs. high dose were compared and significant differences were 
found only in the percentage of drug dissolved at 15 and 60 min 
with USP Apparatus 4 (*P<0.05). 
Table 3: Model-independent parameters of carbamazepine, mean±SEM, n = 12 
USP Apparatus Dose Diss. at 15 min (%) Diss. at 60 min (%) MDT (min) DE (%) 
2 Low 66.97±1.13 94.05±1.50 12.85±0.16 73.90±1.18 
High 67.75±0.95 92.77±1.66 11.95±0.43 73.93±1.00 
4 Low 12.77±0.83 32.26±1.03 23.68±0.67 19.58±0.85 
High 9.76±0.51* 25.30±0.95* 23.31±0.44 15.45±0.56 
*P<0.05, Low vs. High dose. 
 
Dissolution performance of carbamazepine from reference tablets shows 
a dependence on the hydrodynamic conditions to which tablets were 
subjected. Statistical comparison of model-independent parameters 
MDT and DE confirm this result. No significant differences were found 
between doses in each USP apparatus (*P>0.05) but between USP 
apparatuses each dose was totally different. 
Dissolution profiles comparison were carried out with model-
independent parameters MDT and DE. MDT is the time interval 
necessary to dissolve 63.2% of the drug contained in the 
pharmaceutical dosage form and it was calculated according to 
statistical moment’s theory [23]. On the other hand, DE is the area 
under the dissolution curve up to a certain time t, expressed as a 
percentage of the area of the rectangle described by 100% 
dissolution in the same time [24]; so, while MDT is related to 
dissolution rate, DE is related to drug dissolution extent. Cardot et 
al., [25] remark that these model-independent parameters have 
been proposed as adequate parameters for some IVIVC levels. IVIVC 
Level B is based on the comparison of parameters calculated by 
statistical moment’s theory as MDT is while Level C requires the 
calculation of an in vitro parameter that expresses a global drug 
dissolution performance as is the case of DE. 
Medina-Lopez et al. 




Table 4: Criteria used for selection of the best-fit model, mean, n = 12 
Dose First-order Higuchi Korsmeyer-Peppas Hixson-Crowell Makoid-Banakar Weibull Logistic 
R2 adjusted 
2 Low 0.7321 0.5455 0.9814 0.4621 0.9954 0.9971 0.9733 
High 0.6002 0.3488 0.9707 0.2511 0.9956 0.9985 0.9813 
4 Low 0.9396 0.9228 0.9815 0.9222 0.9968 0.9975 0.9905 
High 0.9341 0.9173 0.9731 0.9208 0.9972 0.9978 0.9814 
AIC 
2 Low 78.67 86.10 48.43 87.48 30.40 20.86 50.97 
High 80.02 87.77 51.77 88.66 28.18 11.80 38.84 
4 Low 44.11 52.46 34.18 48.16 13.34 10.77 24.50 
High 44.61 48.39 33.40 47.04 8.59 4.69 27.65 
 
As Weibull function was the best-fit model Td values were calculated and dissolution profiles were compared with these values. No significant 
differences were found between low and high dose (*P>0.05). Results are shown in table 5. 
Table 5: Weibull parameters and Td values derived from data adjusted to this mathematical model, m
USP Apparatus 
ean, n = 12 
Dose α β F Td (±SEM) max 
2 Low 4.56 0.53 109.55 17.72±1.31 
High 4.40 0.57 103.50 14.66±2.15 
4 Low 58.02 1.11 40.25 39.42±4.21 
High 77.27 1.22 30.34 35.94±3.99 
*P<0.05, Low vs. High dose. 
 
Model-dependent comparisons 
Considering established criteria to choose the best-fit model (highest 
R2adjusted and lowest AIC values) Weibull function was the best 
mathematical model to explain in vitro dissolution performance of 
carbamazepine from reference tablets. Results are shown in table 4. 
In this in vitro equivalence study of low and high dose, data fitting to 
mathematical equations previously described were carried out 
without any physiological significance in order to find a 
mathematical model that explains the in vitro dissolution behavior of 
carbamazepine from Mexican reference products. The purpose of 
using mathematical models to adjust in vitro dissolution data is that 
they facilitate the analysis and interpretation of observed results 
and because they describe the dissolution profiles as a function of 
only a few parameters that can be easily statistically compared [26]. 
Dissolution study of two doses of carbamazepine reference tablets 
carried out with USP paddle apparatus and flow-through cell method 
reveals similar dissolution profiles in each USP apparatus. The 
manufacturing process of reference tablets and dissolution conditions 
used allowed the complete release of the drug under official conditions. 
It is important to highlight that these reference tablets show congruence 
between doses in two different systems what represents a product of 
good quality and ensures the proper biowaiver of low dose. This is not 
always the case. Medina et al., [27] studied two doses of metronidazole 
reference tablets (250-mg and 500-mg) using USP basket apparatus and 
flow-through cell method with pharmacopeial dissolution medium (0.1 
N hydrochloric acid) and dissolution process was different in each dose 
and in each USP apparatus. 
Despite low solubility of carbamazepine, it is significant the 
compliance of pharmacopeial criteria of 400-mg tablets (dissolution 
criteria at 15 and 60 min are only for 200-mg tablets) however, the 
main problem identified in this comparative study was the low 
dissolution rate and extent of carbamazepine with USP Apparatus 4. 
The flow-through cell apparatus is an equipment that better reflects 
in vivo environment of the gastrointestinal tract and it is an 
appropriate option to find a significant IVIVC for drugs with 
solubility problems. On this apparatus, several authors have 
reported a better estimate of absorption rate (which is a better 
predictor of in vivo dissolution) of cilostazol and diclofenac sodium 
[15, 16] both poorly soluble drugs. 
In order to develop suitable in vitro dissolution tests, it is important 
to document dissolution performance of all carbamazepine doses of 
reference tablets in dissolution media with pH of physiological 
relevance (pH 1.2, 4.5, and 6.8) as well as studies with flow-through 
cell method. Satisfactory dissolution conditions should predict in 
vivo absorption to avoid clinical problems. Several authors have 
found significant differences in plasma patients undergoing therapy 
with this drug [28] and loss of seizure control when a drug product 
is exchanged for another formulation [29]. In the present in vitro 
equivalence study, similar dissolution performance of two doses of 
carbamazepine reference tablets, independently of USP apparatus 
used, was found. The study was carried out with 1% sodium lauryl 
sulfate aqueous solution as dissolution medium. If this performance 
is observed with dissolution media of physiological relevance it is 
possible to suggest waiver of in vivo studies for lower 
carbamazepine dose since bioavailability will be proportional to the 
highest dose. More research on this field is necessary for all available 
doses of reference drug products since the quality of generic 
formulations depends on the quality of references. 
Similar dissolution performance of two doses of carbamazepine 
reference tablets was found in each USP dissolution apparatus used. 
CONCLUSION 
Dissolution performance of carbamazepine shows a dependence on 
the hydrodynamic conditions to which tablets were subjected. The 
main problem identified in this comparative study is the low 
dissolution rate and extent found with USP Apparatus 4. 
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